Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smartwatches keep watch on heart risks for leukemia patients

NCT ID NCT06211413

First seen Apr 01, 2026 · Last updated May 20, 2026 · Updated 14 times

Summary

This study watches 50 adults with chronic lymphocytic leukemia who are starting certain drugs (acalabrutinib or zanabrutinib). These drugs can cause high blood pressure and irregular heartbeats. Participants will use wearable devices at home to track their heart rhythm and blood pressure. The goal is to learn how often these heart problems happen, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Abramson Cancer Center at University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.